ATE453637T1 - N-(aminoheteroaryl)-1h-indol-2-carboxamid- derivate sowie deren herstellung und therapeutische anwendung - Google Patents

N-(aminoheteroaryl)-1h-indol-2-carboxamid- derivate sowie deren herstellung und therapeutische anwendung

Info

Publication number
ATE453637T1
ATE453637T1 AT07823371T AT07823371T ATE453637T1 AT E453637 T1 ATE453637 T1 AT E453637T1 AT 07823371 T AT07823371 T AT 07823371T AT 07823371 T AT07823371 T AT 07823371T AT E453637 T1 ATE453637 T1 AT E453637T1
Authority
AT
Austria
Prior art keywords
aminoheteroaryl
indole
production
therapeutic use
carboxamide derivatives
Prior art date
Application number
AT07823371T
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Andre Malanda
David Machnik
Catherine Gille
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE453637T1 publication Critical patent/ATE453637T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07823371T 2006-07-31 2007-07-30 N-(aminoheteroaryl)-1h-indol-2-carboxamid- derivate sowie deren herstellung und therapeutische anwendung ATE453637T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606988A FR2904316B1 (fr) 2006-07-31 2006-07-31 Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
PCT/FR2007/001316 WO2008015335A1 (fr) 2006-07-31 2007-07-30 Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE453637T1 true ATE453637T1 (de) 2010-01-15

Family

ID=37806631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07823371T ATE453637T1 (de) 2006-07-31 2007-07-30 N-(aminoheteroaryl)-1h-indol-2-carboxamid- derivate sowie deren herstellung und therapeutische anwendung

Country Status (36)

Country Link
US (2) US7786104B2 (de)
EP (1) EP2049525B1 (de)
JP (1) JP5306201B2 (de)
KR (1) KR20090033885A (de)
CN (1) CN101511819B (de)
AR (1) AR062143A1 (de)
AT (1) ATE453637T1 (de)
AU (1) AU2007280326B2 (de)
BR (1) BRPI0715199A2 (de)
CA (1) CA2658799C (de)
CL (1) CL2007002169A1 (de)
CO (1) CO6150179A2 (de)
CY (1) CY1109944T1 (de)
DE (1) DE602007004119D1 (de)
DK (1) DK2049525T3 (de)
EA (1) EA017375B1 (de)
ES (1) ES2338610T3 (de)
FR (1) FR2904316B1 (de)
HR (1) HRP20100121T1 (de)
IL (1) IL196571A0 (de)
JO (1) JO2644B1 (de)
MA (1) MA30695B1 (de)
ME (1) ME00590A (de)
MX (1) MX2009001222A (de)
MY (1) MY145031A (de)
NO (1) NO20090952L (de)
NZ (1) NZ574345A (de)
PE (1) PE20080688A1 (de)
PL (1) PL2049525T3 (de)
PT (1) PT2049525E (de)
RS (1) RS51235B (de)
SI (1) SI2049525T1 (de)
TW (1) TW200813023A (de)
UY (1) UY30518A1 (de)
WO (1) WO2008015335A1 (de)
ZA (1) ZA200900505B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) * 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
UY34993A (es) 2012-08-28 2014-02-28 Janssen R & D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6419155B2 (ja) 2013-04-03 2018-11-07 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
JO3583B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
HRP20181863T1 (hr) 2013-05-17 2018-12-28 Janssen Sciences Ireland Uc Derivati sulfamoiltiofenamida i njihova uporaba kao lijekova za liječenje hepatitisa b
NO3024819T3 (de) 2013-07-25 2018-07-21
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
HK1247147A1 (zh) 2015-03-19 2018-09-21 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
JP2021515769A (ja) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤の投薬レジメン
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL106957C (de) 1958-09-30
US4104385A (en) 1976-08-19 1978-08-01 Sterling Drug Inc. Cyclic alkylidenyl N-[6-(amino)-3-pyridazinyl]aminomethylenemalonates
EP1347982B1 (de) 2000-12-12 2005-11-16 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-one und 3h-spiroisobenzofuran-1,4'-piperidine
FR2832148B1 (fr) * 2001-11-14 2004-05-21 Oreal Nouvelles bases d'oxydation 2,5-diaminopyridine utiles pour la teinture des fibres keratiniques
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
ATE359782T1 (de) 2003-01-16 2007-05-15 Sb Pharmco Inc Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
EP1673355A1 (de) 2003-09-22 2006-06-28 Pfizer Limited Substituierte triazolderivate als oxytocinantagonisten
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
WO2006040522A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinoline derivatives
US7875627B2 (en) * 2004-12-07 2011-01-25 Abbott Laboratories Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
JP5076091B2 (ja) * 2005-11-28 2012-11-21 マドリガル・ファーマシューティカルズ・インコーポレーテッド ジアシルグリセロールアシルトランスフェラーゼ（ｄｇａｔ）のインヒビター

Also Published As

Publication number Publication date
AU2007280326A1 (en) 2008-02-07
ZA200900505B (en) 2010-04-28
DK2049525T3 (da) 2010-05-03
EP2049525B1 (de) 2009-12-30
RS51235B (sr) 2010-12-31
EA200970171A1 (ru) 2009-06-30
PE20080688A1 (es) 2008-07-24
ES2338610T3 (es) 2010-05-10
UY30518A1 (es) 2008-02-29
MY145031A (en) 2011-12-15
CA2658799A1 (fr) 2008-02-07
CN101511819B (zh) 2014-04-23
BRPI0715199A2 (pt) 2013-10-01
CO6150179A2 (es) 2010-04-20
MA30695B1 (fr) 2009-09-01
EP2049525A1 (de) 2009-04-22
PL2049525T3 (pl) 2010-07-30
ME00590A (en) 2011-12-20
CL2007002169A1 (es) 2008-03-07
AR062143A1 (es) 2008-10-15
AU2007280326B2 (en) 2012-11-29
NO20090952L (no) 2009-04-23
CY1109944T1 (el) 2014-09-10
SI2049525T1 (sl) 2010-04-30
JP2009545574A (ja) 2009-12-24
HRP20100121T1 (hr) 2010-04-30
KR20090033885A (ko) 2009-04-06
CN101511819A (zh) 2009-08-19
US20090156573A1 (en) 2009-06-18
MX2009001222A (es) 2009-02-13
FR2904316A1 (fr) 2008-02-01
US7786104B2 (en) 2010-08-31
WO2008015335A1 (fr) 2008-02-07
EA017375B1 (ru) 2012-12-28
US20100286119A1 (en) 2010-11-11
CA2658799C (fr) 2014-10-07
US8586573B2 (en) 2013-11-19
JO2644B1 (en) 2012-06-17
IL196571A0 (en) 2009-11-18
DE602007004119D1 (de) 2010-02-11
NZ574345A (en) 2011-11-25
PT2049525E (pt) 2010-03-23
TW200813023A (en) 2008-03-16
JP5306201B2 (ja) 2013-10-02
FR2904316B1 (fr) 2008-09-05

Similar Documents

Publication Publication Date Title
DE602007004119D1 (de) N-(aminoheteroaryl)-1h-indol-2-carboxamid-derivate sowie deren herstellung und therapeutische anwendung
ATE461930T1 (de) Harnstoffderivate von tropan, ihre herstellung und ihre therapeutische anwendung
IL196113A0 (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
ATE475661T1 (de) Triazolopyridin-carboxamid-derivate sowie ihre herstellung und therapeutische verwendung
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
ATE372998T1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
EP2152304A4 (de) Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
EP2341047A4 (de) Cyclohexanderivat und pharmazeutische anwendung davon
DE602006020061D1 (de) Mucin-glycoprotein und anwendung davon
ATE548349T1 (de) In stellung 3 disubstituierte indol-2-on- pyridinderivate, ihre herstellung sowie ihre therapeutische anwendung
EP2001833A4 (de) Antidiabetische cataractverbindungen und deren anwendung
ATE420081T1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
DE602006017183D1 (de) Benzimidazolderivat und anwendung davon
ATE499351T1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung
ATE423119T1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
PL377180A1 (pl) Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
DE602006015675D1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
ATE549339T1 (de) Derivate von pyrrolopyridin-2-carboxamiden, ihre herstellung und ihre therapeutische anwendung
ATE543496T1 (de) 3-acylindol-derivate sowie deren herstellung und therapeutische anwendung
ATE524468T1 (de) Derivate aus n-phenyl-imidazo-(1,2-a)-pyridin-2- carboxamiden, ihre herstellung sowie ihre therapeutische anwendung
ATE441643T1 (de) N-ä(4,5-diphenylpyrimidin-2- yl)methylüaminderivate, deren herstellung und deren therapeutische verwendung
ATE533767T1 (de) Derivate aus n-heterozyklischen-6- heterozyklischen imidazo-ä1,2-aü-pyridin-2- carboxamiden, ihre herstellung und ihre therapeutische anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2049525

Country of ref document: EP